159992 创新药
交易中 02-12 09:48:51
资讯
新帖
简况
国信证券：医药生物行业关注低估值和业绩修复的服务及消费板块 创新药出海合作持续深化
智通财经 · 31分钟前
国信证券：医药生物行业关注低估值和业绩修复的服务及消费板块 创新药出海合作持续深化
【ETF动向】2月11日银华中证创新药产业ETF基金跌0.24%，份额减少9420万份
证券之星 · 08:04
【ETF动向】2月11日银华中证创新药产业ETF基金跌0.24%，份额减少9420万份
恒瑞医药：公司自主研发的1类创新药瑞拉芙普α注射液已于2026年1月在国内获批上市
证券日报 · 02-11 19:37
恒瑞医药：公司自主研发的1类创新药瑞拉芙普α注射液已于2026年1月在国内获批上市
博安生物股价波动，创新药复苏或带来间接影响
经济观察网 · 02-11 16:38
博安生物股价波动，创新药复苏或带来间接影响
华东医药：创新药海外授权合作是涉及商务、法规、市场及战略匹配的复杂过程
证券之星 · 02-11 11:33
华东医药：创新药海外授权合作是涉及商务、法规、市场及战略匹配的复杂过程
【ETF动向】2月10日华宝恒生港股通创新药精选ETF基金涨2.9%，份额减少7800万份
证券之星 · 02-11 06:32
【ETF动向】2月10日华宝恒生港股通创新药精选ETF基金涨2.9%，份额减少7800万份
上海医药原研1.1类创新药苹果酸司妥吉仑片在浦东开出首张处方
人民财讯 · 02-10 18:05
上海医药原研1.1类创新药苹果酸司妥吉仑片在浦东开出首张处方
华商基金刘力：2026年关注国产AI、创新药、商业航天三大领域
新浪基金 · 02-10 12:10
华商基金刘力：2026年关注国产AI、创新药、商业航天三大领域
创新药概念股普遍走高 石药集团涨超7%药明生物涨超5%
新浪港股 · 02-10 11:34
创新药概念股普遍走高 石药集团涨超7%药明生物涨超5%
中国创新药BD交易进入“后签约时代”，争议解决或成行业必修课
21世纪经济报道 · 02-10 11:23
中国创新药BD交易进入“后签约时代”，争议解决或成行业必修课
港股异动 | CRO概念股涨幅居前 创新药投融资与BD出海同步回暖 行业景气度有望逐步改善
智通财经 · 02-10 10:55
港股异动 | CRO概念股涨幅居前 创新药投融资与BD出海同步回暖 行业景气度有望逐步改善
6天6阳，港股通医疗、港股通创新药正加速回暖！
每日经济新闻 · 02-10 10:38
6天6阳，港股通医疗、港股通创新药正加速回暖！
恒生医疗保健指数升2.17% 医药板块普遍拉升 机构持续看好中国创新药出海的产业趋势
金吾财讯 · 02-10 09:59
恒生医疗保健指数升2.17% 医药板块普遍拉升 机构持续看好中国创新药出海的产业趋势
【ETF动向】2月9日华宝恒生港股通创新药精选ETF基金涨1.77%，份额减少6800万份
证券之星 · 02-10 06:31
【ETF动向】2月9日华宝恒生港股通创新药精选ETF基金涨1.77%，份额减少6800万份
震撼88.5亿美金！天价创新药BD点火，520880摸高2.75%，港股通医疗ETF（159137）五连阳！机构提示低位机遇
新浪基金 · 02-09 19:36
震撼88.5亿美金！天价创新药BD点火，520880摸高2.75%，港股通医疗ETF（159137）五连阳！机构提示低位机遇
出海新变量｜从产品授权到平台合作，创新药出海迈入新阶段
第一财经 · 02-09 18:10
出海新变量｜从产品授权到平台合作，创新药出海迈入新阶段
中国创新药龙头大涨近7%，拿下国际巨头88亿美元合作，首付3.5亿美元
21世纪经济报道 · 02-09 13:42
中国创新药龙头大涨近7%，拿下国际巨头88亿美元合作，首付3.5亿美元
88.5亿美元！千亿创新药巨头又有大动作
中国基金报 · 02-08
88.5亿美元！千亿创新药巨头又有大动作
众生药业最新公告：控股子公司一类创新药昂拉地韦项目两项III期临床试验获积极结果
证券之星 · 02-08
众生药业最新公告：控股子公司一类创新药昂拉地韦项目两项III期临床试验获积极结果
每周股票复盘：福元医药（601089）创新药FY101进入I期临床
证券之星 · 02-08
每周股票复盘：福元医药（601089）创新药FY101进入I期临床
加载更多
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"159992","market":"SZ","secType":"STK","nameCN":"创新药","latestPrice":0.845,"timestamp":1770860931000,"preClose":0.846,"halted":0,"volume":92004900,"delay":0,"changeRate":-0.0012,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":-0.001,"latestTime":"02-12 09:48:51","open":0.846,"high":0.853,"low":0.844,"amount":78061700,"amplitude":0.0106,"askPrice":0.846,"askSize":83491,"bidPrice":0.845,"bidSize":54001,"shortable":0,"etf":1,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1770867000000},"marketStatusCode":2,"adr":0,"adjPreClose":0.846,"symbolType":"fund","openAndCloseTimeList":[[1770859800000,1770867000000],[1770872400000,1770879600000]],"highLimit":0.931,"lowLimit":0.761,"ibTradeSell":false,"ibTradeBuySell":true,"isCdr":false,"pbRate":0,"committee":0.444277,"marketValue":0,"turnoverRate":0,"status":1,"floatMarketCap":0},"requestUrl":"/m/hq/s/159992","defaultTab":"news","newsList":[{"id":"2610957679","title":"国信证券：医药生物行业关注低估值和业绩修复的服务及消费板块 创新药出海合作持续深化","url":"https://stock-news.laohu8.com/highlight/detail?id=2610957679","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610957679?lang=zh_cn&edition=full","pubTime":"2026-02-12 09:18","pubTimestamp":1770859099,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国信证券发布研报称，医疗服务和消费相关等板块经历长期调整后估值处于历史低位。同时，国产创新药出海持续深化，中国创新药的研发效率与成本优势获国际认可。创新药出海合作持续深化近期，石药集团和信达生物分别与阿斯利康和礼来达成重磅合作协议。国产创新药的出海仍在继续，基于技术平台的多项目的合作协议表明了中国创新药的研发能力不断获得跨国药企的认可，中国创新药的效率优势、成本优势得到持续的体现。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","06978","BK1161","BK0183","000808.SH","BK0276","159992","002736","BK0188","163118","BK0028"],"gpt_icon":0},{"id":"2610099880","title":"【ETF动向】2月11日银华中证创新药产业ETF基金跌0.24%，份额减少9420万份","url":"https://stock-news.laohu8.com/highlight/detail?id=2610099880","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610099880?lang=zh_cn&edition=full","pubTime":"2026-02-12 08:04","pubTimestamp":1770854663,"startTime":"0","endTime":"0","summary":"证券之星消息，2月11日，银华中证创新药产业ETF基金（159992）跌0.24%，成交额4亿元。当日份额减少了9420万份，最新份额为183.51亿份，近20个交易日份额增加19.06亿份。当日资金净流出9453.41万元（资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的），最新资产净值计算值为155.41亿元。银华中证创新药产业ETF基金跟踪标的为中证创新药产业指数，成立（2020-03-20）以来超额回报为-7.63%，近一个月超额回报为0.01%，管理人为银华基金公司，基金经理为马君 王帅。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021200005020.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","159992","BK1574","BK1161"],"gpt_icon":0},{"id":"2610993166","title":"恒瑞医药：公司自主研发的1类创新药瑞拉芙普α注射液已于2026年1月在国内获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2610993166","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610993166?lang=zh_cn&edition=full","pubTime":"2026-02-11 19:37","pubTimestamp":1770809832,"startTime":"0","endTime":"0","summary":"证券日报网讯2月11日，恒瑞医药在互动平台回答投资者提问时表示，公司坚持差异化研发策略，以临床需求为导向，利用领先的技术平台打造差异化创新产品矩阵。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602113648077695.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0359201612.USD","LU1255011170.USD","LU1655091616.SGD","LU1997245177.USD","LU2543165471.USD","LU1969619763.USD","LU2097828805.USD","01276","LU1328615791.USD","LU1781817850.SGD","LU1023057109.AUD","LU0359201885.HKD","LU1997245094.SGD","LU1146622755.USD","159992","BK0188","LU0405327148.USD","BK1574","BK1191","BK1161","LU0359202008.SGD","LU1997244956.HKD","LU2289578879.USD","LU2328871848.SGD","BK0060","LU2097828474.EUR","06978","LU2097828714.EUR","LU2148510915.USD","BK0028","BK0012","LU2097828631.EUR","LU2495084118.USD","BK0196","LU0405327494.USD","LU1580142542.USD","BK0239","LU1064131003.USD","BK0183","LU1820825898.SGD","LU1064130708.USD","LU2488822045.USD","LU2097828557.USD","LU2580892789.USD","600276","LU2580892862.HKD"],"gpt_icon":0},{"id":"2610650982","title":"博安生物股价波动，创新药复苏或带来间接影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2610650982","media":"经济观察网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610650982?lang=zh_cn&edition=full","pubTime":"2026-02-11 16:38","pubTimestamp":1770799080,"startTime":"0","endTime":"0","summary":"经济观察网近期，创新药行业呈现复苏迹象，投融资回暖、出海规模创新高及审评效率提升等因素，可能间接影响博安生物等生物技术公司。股票近期走势近一周，博安生物股价波动，区间涨跌幅为0. ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260211/c674728581.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260211/c674728581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159992"],"gpt_icon":0},{"id":"2610060144","title":"华东医药：创新药海外授权合作是涉及商务、法规、市场及战略匹配的复杂过程","url":"https://stock-news.laohu8.com/highlight/detail?id=2610060144","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610060144?lang=zh_cn&edition=full","pubTime":"2026-02-11 11:33","pubTimestamp":1770780797,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药02月10日在投资者关系平台上答复投资者关心的问题。为啥别人能做到一个接一个的大单华东医药回复：您好！创新药海外授权合作是涉及商务、法规、市场及战略匹配的复杂过程。公司始终秉持开放合作战略，在强化自主研发的同时，积极与全球同行一起探索创新药管线的BD机会。未来如达成明确合作协议，公司将严格按照信息披露规则履行披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021100014208.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2328871848.SGD","06978","BK0183","BK0187","BK0209","BK1574","BK0175","000963","BK0132","LU1969619763.USD","BK0196","BK0188","BK1161","159992"],"gpt_icon":0},{"id":"2610674045","title":"【ETF动向】2月10日华宝恒生港股通创新药精选ETF基金涨2.9%，份额减少7800万份","url":"https://stock-news.laohu8.com/highlight/detail?id=2610674045","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610674045?lang=zh_cn&edition=full","pubTime":"2026-02-11 06:32","pubTimestamp":1770762733,"startTime":"0","endTime":"0","summary":"证券之星消息，2月10日，华宝恒生港股通创新药精选ETF基金（520880）涨2.9%，成交额5.9亿元。当日份额减少了7800万份，最新份额为46.12亿份，近20个交易日份额增加5.26亿份。当日资金净流入2065.75万元（资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的），最新资产净值计算值为24.66亿元。华宝恒生港股通创新药精选ETF基金跟踪标的为恒生港股通创新药精选指数，成立（2025-06-27）以来超额回报为-4.1%，近一个月超额回报为-0.45%，管理人为华宝基金公司，基金经理为丰晨成。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021100003538.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","06978","159992","BK1161"],"gpt_icon":0},{"id":"2610645934","title":"上海医药原研1.1类创新药苹果酸司妥吉仑片在浦东开出首张处方","url":"https://stock-news.laohu8.com/highlight/detail?id=2610645934","media":"人民财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610645934?lang=zh_cn&edition=full","pubTime":"2026-02-10 18:05","pubTimestamp":1770717948,"startTime":"0","endTime":"0","summary":"人民财讯2月10日电，2月10日，我国1.1类创新药——苹果酸司妥吉仑片（商品名“信妥安”），在上海市浦东新区公利医院开出首张处方。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602103646780111.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","BK0028","BK0099","BK0187","BK0020","BK0183","BK0175","BK0097","BK1161","159992","BK0184","BK1197","BK0012","601607","BK0188","BK0196","BK1574","BK0209","02607"],"gpt_icon":0},{"id":"2610925346","title":"华商基金刘力：2026年关注国产AI、创新药、商业航天三大领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2610925346","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610925346?lang=zh_cn&edition=full","pubTime":"2026-02-10 12:10","pubTimestamp":1770696600,"startTime":"0","endTime":"0","summary":"新春将至，站在农历马年的新起点上，未来哪些领域会以奔腾之姿引领市场风潮，投资者该如何布局？ 对此，华商新动力混合基金经理刘力近日表示，2026年较为关注三大方向。首先是国产AI生态，或将在今年迎来全面爆发；二是创新药，产业崛起的趋势不变，将精选其中具备超额收益的标的；三是处于技术“0到1”突破阶段的商业航天领域，值得持续跟踪，捕捉产业链卡位核心的品种。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-02-10/doc-inhmiaek4668618.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","159992","BK1574","BK4564","UFO","06978"],"gpt_icon":0},{"id":"2610943736","title":"创新药概念股普遍走高 石药集团涨超7%药明生物涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610943736","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610943736?lang=zh_cn&edition=full","pubTime":"2026-02-10 11:34","pubTimestamp":1770694440,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 创新药概念股午前普遍走高，截至发稿，石药集团（01093）上涨7.16%，报10.48港元；药明生物（02269）上涨5.54%，报40.36港元；康诺亚-B（02162）上涨5.45%，报60.95港元；信达生物（01801）上涨5.15%，报89.8港元；再鼎医药（09688）上涨4.9%，报14.76港元。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-02-10/doc-inhmiaep8549540.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1576","LU1807302812.USD","SG9999002562.SGD","BK1574","LU0516423174.USD","BK1515","LU1688375341.USD","LU1794554557.SGD","IE00BZ08YT58.USD","LU0327786744.USD","02269","LU0348825331.USD","LU0320764599.SGD","HK0000165453.HKD","LU0359201612.USD","LU0501845795.SGD","06978","LU0588546209.SGD","LU2039709279.SGD","BK1191","BK1141","LU0359202008.SGD","LU0039217434.USD","LU0417516902.SGD","01093","LU0326950275.SGD","LU1152091754.HKD","LU0979878070.USD","LU1152091168.USD","BK1161","LU1242518857.USD","LU0456827905.SGD","LU0880133367.SGD","159992","LU1993786604.SGD","LU0052750758.USD","LU1226287875.USD","LU1813983027.USD","LU3063872942.SGD","LU0516423091.SGD","LU0708995583.HKD","BK1521","LU1242518931.SGD","LU1226287529.USD","IE00B543WZ88.USD","LU1880383366.USD","IE0008368742.USD","IE00B031HY20.USD","BK1610","LU0456846285.SGD"],"gpt_icon":0},{"id":"2610694688","title":"中国创新药BD交易进入“后签约时代”，争议解决或成行业必修课","url":"https://stock-news.laohu8.com/highlight/detail?id=2610694688","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610694688?lang=zh_cn&edition=full","pubTime":"2026-02-10 11:23","pubTimestamp":1770693826,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者韩利明2025年，中国创新药行业迈入新十年发展周期，BD（商务拓展）交易持续升温，行业出海势能加速释放。国家药监局数据显示，全年中国创新药BD交易总金额达1356.55亿美元，交易数量达157笔，两项核心指标均刷新历史纪录，印证中国创新药在全球市场的吸引力持续攀升。伴随BD热潮的推进，此前布局的合作项目逐步进入里程碑收获期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602103646488349.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602103646488349.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","06978","159992","BK1574"],"gpt_icon":0},{"id":"2610699139","title":"港股异动 | CRO概念股涨幅居前 创新药投融资与BD出海同步回暖 行业景气度有望逐步改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2610699139","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610699139?lang=zh_cn&edition=full","pubTime":"2026-02-10 10:55","pubTimestamp":1770692111,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，CRO概念股涨幅居前，截至发稿，维亚生物涨6.14%，报2.42港元；药明生物涨6.01%，报40.54港元；泰格医药涨4.65%，报56.3港元；药明康德涨4.31%，报121港元。消息面上，2025年药明康德净利润预计同比增加103%，泰格医药同比增加105-204%。国泰海通证券发布研报称，随着融资与BD回款回升，药企重新加大临床试验投入，对临床CRO、SMO及注册服务的外包需求同步恢复，为行业景气度回升提供直接资金来源与项目基础。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403526.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999002562.SGD","02359","VT","02269","LU2039709279.SGD","LU0348825331.USD","BK1141","LU1720050803.USD","LU0359202008.SGD","06978","LU0320764599.SGD","LU0516422952.EUR","LU1794554557.SGD","LU0456846285.SGD","BK1574","LU0417516738.SGD","BK4588","BK1521","LU0516423174.USD","LU0823426480.USD","BK1161","LU0326950275.SGD","LU0516422366.SGD","159992","BK1610","LU1688375341.USD","LU2045819591.USD","LU0043850808.USD","LU0348735423.USD","LU0572944931.SGD","03347","LU1242518931.SGD","LU1880383366.USD","LU0823426308.USD","LU0819121731.USD","LU2125910500.SGD","LU0052750758.USD","LU0359201612.USD","SG9999002463.SGD","LU0051755006.USD","IE00B0JY6N72.USD","LU0856984785.SGD","LU2242644610.SGD","BK1589","VXUS","LU0516423091.SGD","01873","LU0181495838.USD","LU0516422440.USD","BK1583"],"gpt_icon":0},{"id":"2610699626","title":"6天6阳，港股通医疗、港股通创新药正加速回暖！","url":"https://stock-news.laohu8.com/highlight/detail?id=2610699626","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610699626?lang=zh_cn&edition=full","pubTime":"2026-02-10 10:38","pubTimestamp":1770691080,"startTime":"0","endTime":"0","summary":"2月份以来，港股医药、医疗以一波强势连阳行情，持续修复失地。热门ETF方面，2月10日，港股通创新药ETF(520880)、港股通医疗ETF(159137)早盘悉数涨逾2%，其中，港股通创新药ETF(520880)涨幅 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260210/c674686375.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260210/c674686375.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159992","159891"],"gpt_icon":0},{"id":"2610268695","title":"恒生医疗保健指数升2.17% 医药板块普遍拉升 机构持续看好中国创新药出海的产业趋势","url":"https://stock-news.laohu8.com/highlight/detail?id=2610268695","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610268695?lang=zh_cn&edition=full","pubTime":"2026-02-10 09:59","pubTimestamp":1770688793,"startTime":"0","endTime":"0","summary":"2月8日，信达生物宣布与礼来制药达成战略合作，携手推进肿瘤及免疫领域创新药物的全球研发。2026年，继续看好中国创新药出海的产业趋势，继续重点跟踪ADC、双抗、小核酸、减肥药等核心优势赛道的投资机会，期待JPM大会、ASCO等带来数据更新和BD催化。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8f73ea90e21e93e4b02cf2f8986a9c30","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1974845","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","LU1720050803.USD","LU2039709279.SGD","LU0516423174.USD","LU0140636845.USD","01548","LU2476274308.USD","IE00B5MMRT66.SGD","03347","LU0196878994.USD","LU1046422090.SGD","LU0181495838.USD","LU0359202008.SGD","LU0348825331.USD","09939","02162","159992","LU2045819591.USD","06990","09926","02268","LU0502904849.HKD","01877","01801","02269","LU0634319403.HKD","02359","LU1688375341.USD","09969","LU0051755006.USD","LU0572944931.SGD","LU1961090484.USD","BK1161","LU0823426308.USD","LU1969619763.USD","02696","LU0417516738.SGD","LU0417516902.SGD","LU2242644610.SGD","LU0043850808.USD","LU0856984785.SGD","LU2476274720.SGD","LU2488822045.USD","09688","BK1587","LU0516422366.SGD","09995","159938","HK0000306701.USD","159506"],"gpt_icon":1},{"id":"2610166452","title":"【ETF动向】2月9日华宝恒生港股通创新药精选ETF基金涨1.77%，份额减少6800万份","url":"https://stock-news.laohu8.com/highlight/detail?id=2610166452","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610166452?lang=zh_cn&edition=full","pubTime":"2026-02-10 06:31","pubTimestamp":1770676297,"startTime":"0","endTime":"0","summary":"证券之星消息，2月9日，华宝恒生港股通创新药精选ETF基金（520880）涨1.77%，成交额3.81亿元。当日份额减少了6800万份，最新份额为46.9亿份，近20个交易日份额增加6.04亿份。当日资金净流入1068.69万元（资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的），最新资产净值计算值为24.46亿元。华宝恒生港股通创新药精选ETF基金跟踪标的为恒生港股通创新药精选指数，成立（2025-06-27）以来超额回报为-4.03%，近一个月超额回报为-0.46%，管理人为华宝基金公司，基金经理为丰晨成。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000004124.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK1574","BK1161","159992"],"gpt_icon":0},{"id":"2610321436","title":"震撼88.5亿美金！天价创新药BD点火，520880摸高2.75%，港股通医疗ETF（159137）五连阳！机构提示低位机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2610321436","media":"新浪基金","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610321436?lang=zh_cn&edition=full","pubTime":"2026-02-09 19:36","pubTimestamp":1770636960,"startTime":"0","endTime":"0","summary":"2月9日，港股市场全面反弹，港股医药板块延续修复行情。 信达生物拿下88.5亿美元BD大单，无意外全天领涨，最高涨至8.55%，收涨7.42%，龙头股大受提振，百济神州涨超3%，石药集团、中国生物制药、三生制药集体跟涨。 100%创新药研发标的——港股通创新药ETF高开后上探2.75%，收涨1.77%成功连阳，一并站上10日均线，全天成交3.81亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-02-09/doc-inhmfqca5267862.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","520880","159992","159137","BK1161","520510","BK1574"],"gpt_icon":0},{"id":"2610636416","title":"出海新变量｜从产品授权到平台合作，创新药出海迈入新阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2610636416","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610636416?lang=zh_cn&edition=full","pubTime":"2026-02-09 18:10","pubTimestamp":1770631857,"startTime":"0","endTime":"0","summary":"“我们整个交易大概谈了一年时间。”2月9日，信达生物（01801.HK）创始人、董事会主席、首席执行官俞德超对第一财经记者透露。前一天，信达生物宣布与跨国药企礼来达成超88亿美元的重磅交易。通过这笔交易，信达生物将获得3.5亿美元首付款；在达成后续特定里程碑事件后，公司还有资格获得总额最高约85亿美元的研发、监管及商业化里程碑付款。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602093645557827.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602093645557827.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1161","06978","159992"],"gpt_icon":0},{"id":"2610686762","title":"中国创新药龙头大涨近7%，拿下国际巨头88亿美元合作，首付3.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610686762","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610686762?lang=zh_cn&edition=full","pubTime":"2026-02-09 13:42","pubTimestamp":1770615720,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 作者丨韩利明。 2月8日晚间，信达生物宣布与礼来制药达成战略合作，携手推进肿瘤及免疫领域创新药物的全球研发。 条款显示，信达生物将获得3.5亿美元首付款；在达成后续特定里程碑事件后，信达生物还有资格获得总额最高约85亿美元的研发、监管及商业化里程碑付款。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hyyj/2026-02-09/doc-inhmexfp9356794.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hyyj/2026-02-09/doc-inhmexfp9356794.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","159992","BK1161","BK1574"],"gpt_icon":0},{"id":"2609574598","title":"88.5亿美元！千亿创新药巨头又有大动作","url":"https://stock-news.laohu8.com/highlight/detail?id=2609574598","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609574598?lang=zh_cn&edition=full","pubTime":"2026-02-08 22:51","pubTimestamp":1770562260,"startTime":"0","endTime":"0","summary":"【导读】信达生物与礼来制药达成战略合作信达生物2月8日晚公告，公司与礼来制药达成战略合作，携手推进肿瘤及免疫领域创新药物的全球研发进程。根据协议条款，信达生物将获得3.5亿美元首付 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260208/c674640507.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260208/c674640507.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159992"],"gpt_icon":0},{"id":"2609432573","title":"众生药业最新公告：控股子公司一类创新药昂拉地韦项目两项III期临床试验获积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2609432573","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609432573?lang=zh_cn&edition=full","pubTime":"2026-02-08 16:19","pubTimestamp":1770538793,"startTime":"0","endTime":"0","summary":"众生药业(002317.SZ)公告称，公司控股子公司众生睿创的一类创新药物昂拉地韦颗粒治疗2~11岁单纯性甲型流感患者的III期临床试验和昂拉地韦片治疗12~17岁青少年单纯性甲型流感患者的III期临床试验，于近日获得顶线分析数据。初步结果表明，昂拉地韦颗粒在2~11岁单纯性甲型流感参与者、昂拉地韦片在12~17岁单纯性甲型流感参与者中表现出积极的疗效和良好的安全性，试验结果理想，达到预期目的。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800004316.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","002317","BK1574","BK0239","BK1161","BK0077","159992","BK0188"],"gpt_icon":0},{"id":"2609254445","title":"每周股票复盘：福元医药（601089）创新药FY101进入I期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2609254445","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609254445?lang=zh_cn&edition=full","pubTime":"2026-02-08 02:18","pubTimestamp":1770488293,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，福元医药报收于26.6元，较上周的28.9元下跌7.96%。本周，福元医药2月2日盘中最高价报28.77元。本周关注点来自机构调研要点：公司创新药FY101注射液正在按计划进行I期临床实验。来自机构调研要点：公司自主研发新药FY103注射液已获境内临床试验申请受理。小核酸是继小分子和抗体后的第三大类药物，福元医药创新药主要聚焦小核酸及小核酸递送系统的研发。截至目前进展最快的管线在进行I期临床实验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800000679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089","06978","BK1161","159992","BK1574"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770860933777,"stockEarnings":[{"period":"1week","weight":0.0168},{"period":"1month","weight":-0.0569},{"period":"3month","weight":-0.0754},{"period":"6month","weight":-0.0962},{"period":"1year","weight":0.2225},{"period":"ytd","weight":0.0181}],"compareEarnings":[{"period":"1week","weight":0.0073},{"period":"1month","weight":-0.008},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1177},{"period":"1year","weight":0.2453},{"period":"ytd","weight":0.0411}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"创新药,159992,创新药股票,创新药股票老虎,创新药股票老虎国际,创新药行情,创新药股票行情,创新药股价,创新药股市,创新药股票价格,创新药股票交易,创新药股票购买,创新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}